Clinical Trial

Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 12, 2024 (before its estimated July 21, 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this project is to assess the feasibility and safety of administering a single dose of psilocybin to patients diagnosed with alcohol use disorder (AUD). In addition the investigators will establish the pharmacokinetic properties of the active metabolite psilocin. This is the first step in a research project that has the overall aim to evaluate the efficacy of a single administration of psilocybin as an intervention for treatment of AUD.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04718792
Lead Sponsor Anders Fink-Jensen, MD, DMSci
Collaborators: The Neurobiology Research Unit at Copenhagen University Hospital Rigshospitalet
Conditions Alcohol Use Disorder (AUD)
Enrollment 10 participants
Start Date 2023-02-09
Primary Completion 2024-07-21 (estimated)
Study Completion 2024-07-21 (estimated)
Updated on ClinicalTrials.gov 2024-07-12